Aclaris Therapeutics Balance Sheet - Annual (NASDAQ:ACRS)

Add to My Stocks
$15.17 $0.26 (1.69%) ACRS stock closing price Sep 21, 2018 (Closing)

The Aclaris Therapeutics balance sheet is a snapshot of the company's financial health at a given point of time, whereas the other two financial statements are for a particular accounting period. Balance sheet items like cash at hand, total assets and liabilities helps one analyze a company and summarize the financial performance of the company like we have in our Aclaris Therapeutics stock analysis. Annual results announcements include the release of all three financial statements, of which the balance sheet is one. Apart from analyzing Aclaris Therapeutics revenue Aclaris Therapeutics operating cash flow, one needs to check balance sheet items like cash, fixed assets and debt. The Aclaris Therapeutics balance sheet for 2017 shows cash on hand of $20.2M. The company has a debt to equity ratio of .

View latest 10 year balance sheet data to check Aclaris Therapeutics financial performance.
show more
Fiscal year is Jan - Dec20172016201520142013
Cash20.2M30.17M9.85M10.75M9.58M
Marketable Securities173.65M107.05M75.01M5.37M3.73M
Receivables-----
Inventory-----
Raw Materials-----
Work In Progress-----
Finished Goods-----
Notes Receivable-----
Other Current Assets5.88M1.33M1.65M--
Total Current Assets
200.22M138.55M86.52M16.33M13.38M
Property Plant & Equipment2.63M----
Accumulated Depreciation-----
Net Property Plant & Equipment
2.15M----
Investment & Advances14.99M36.91M7.17M--
Other Non-Current Assets-----
Deferred Charges-----
Intangibles25.85M----
Deposits & Other Assets-----
Total Assets
243.5M176.08M94.07M17.37M14.2M
Notes Payable-----
Accounts Payable7.82M2.84M-1.26M-
Current Portion Long-Term Debt-----
Current Portion Capital Leases-----
Accrued Expenses4.94M3.37M---
Income Taxes Payable-----
Other Current Liabilities-----
Total Current Liabilities
12.76M6.22M1.55M1.45M-
Mortgages-----
Deferred Taxes/Income-----
Convertible Debt-----
Long-Term Debt-----
Non-Current Capital Leases-----
Other Long-Term Liabilities4.93M----
Total Liabilities
18.24M6.59M1.55M1.45M-
Minority Interest-----
Preferred Stock---36.67M23M
Common Stock Net-----
Capital Surplus384.94M260.67M135.5M--
Retained Earnings-159.43M-90.91M-42.83M-20.74M-9.16M
Treasury Stock-----
Other Liabilities-0.24M-0.26M-0.14M-0.01M-
Shareholders Equity225.26M169.49M92.52M15.92M13.83M
Total Liabilities & Shareholders Equity243.5M176.08M94.07M17.37M14.2M
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Revance financial analysis

Looking at Aclaris Therapeutics historical stock prices and the current Aclaris Therapeutics stock price can tell you how the stock price has moved, whereas the Aclaris Therapeutics PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:

  • Assets: ACRS total assets, which was at $243.5M for 2017 is a balance sheet item representing value of what Aclaris Therapeutics owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities: The total liabilities of Aclaris Therapeutics for the year 2017 total to $18.24M. Liabilities for a company like Aclaris Therapeutics include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

Aclaris Therapeutics Balance Sheet - Key Ratios

Price to book ratio
2.31

Annual Balance Sheets For Aclaris Therapeutics Inc Peers

Fibrocell Science balance sheet, NOVAN INC balance sheet, Revance balance sheet